



## ASPC 2025 CONGRESS ON CVD PREVENTION SCIENTIFIC SESSIONS AGENDA

*Dates and times subject to change*

### FRIDAY, AUGUST 1, 2025

SESSION	NAME OF SESSION	SPEAKER/MODERATOR
<b>Session 1</b>	<b>Opening Session &amp; Award Lectures</b>	
8:00 – 8:20 AM	Welcome Remarks & President's Address	Michael Shapiro, DO, MCR, FASPC
8:20 – 8:35 AM	Honorary Fellow Award Lecture	Helen Hobbs, MD
8:35 – 8:50 AM	Joseph Stokes III, MD Pioneer in Prevention Award Lecture	Roger Blumenthal, MD, FASPC
8:50 – 9:05 AM	Nanette Wenger Award Lecture	Harmony Reynolds, MD
9:05 – 9:20 AM	American Journal of Preventive Cardiology Editors' Update	Erin Michos, MD, MHS, FASPC
<b>Session 2</b>	<b><i>Bridging Populations and Prevention: How Prospective Cohorts Have Informed Prevention of CVD</i></b>	
9:20 – 9:35 AM	Lessons from Framingham	Matthew Naylor, MD, MPH
9:35 – 9:50 AM	Lessons from Bogalusa	Keith Ferdinand, MD, FASPC
9:50 – 10:05 AM	Lessons from Women's Health Initiative	JoAnn Manson, MD, MPH, DrPH
10:05 – 10:25 AM	Q & A	
<b>10:25 – 11:00 AM</b>	<b><i>Networking Break</i></b>	
<b>Session 3</b>	<b>EAS/ASPC Joint Session – Advances in Lipoprotein(a) Management: Transatlantic Insights</b>	
11:00 – 11:15 AM	Genetics and Pathophysiology of Lipoprotein(a): New Insights	Florian Kronenberg, MD
11:15 – 11:30 AM	Integrating Lipoprotein(a) into Risk Assessment and Management: European vs. American Guidelines	Prof. Dr. Lale Tokgözoğlu
11:30 – 11:45 AM	Lipoprotein(a): Myths, Misconceptions, and Management	Michael Shapiro, DO, MCR, FASPC
11:45 AM – 12:00 PM	Emerging Therapies for Lowering Lipoprotein(a): Clinical Trial Updates	Harpreet Bhatia, MD, MAS, FASPC
12:00 – 12:15 PM	Q & A	
<b>12:30 – 1:15 PM</b>	<b><i>Expert Theater Lunch Presentations</i></b>	

<b>Session 4</b>		<b>Debates in Preventive Cardiology – Round 1</b>	
1:30 – 2:00 PM	The Systolic Blood Pressure Goal Should Be <120 mmHg, Not <130	Paul Whelton, MD, MSc (Pro) vs. Raymond Townsend, MD (Con)	
2:00 – 2:30 PM	Colchicine Should Be Recommended for Secondary Prevention of Coronary Disease	Paul Ridker, MD, MPH (Pro) vs. Sanjit Jolly, MD, MSc (Con)	
2:30 – 3:00 PM	ApoB Measurement Should Replace LDL-Cholesterol	Ann Marie Navar, MD, PhD, FASPC (Pro) vs. Roger Blumenthal, MD, FASPC (Con)	
3:00 – 3:30 PM	Q & A		
<b>3:30 – 4:00 PM</b>	<b>Networking Break</b>		
<b>Session 5</b>		<b>Artificial Intelligence and Technology in the Practice of Preventive Cardiology</b>	
4:00 – 4:15 PM	AI Language Models in Preventive Cardiology: Hope, Hype & Dr. ChatGPT	Ashish Sarraju, MD	
4:15 – 4:30 PM	Opportunistic and Inclusive Prevention: AI and Health Techquity	Fatima Rodriguez, MD, MPH, FASPC	
4:30 – 4:45 PM	Wearables and Mobile Health Technologies for Preventive Cardiology Solutions	Seth Martin, MD, MHS, FASPC	
4:45 – 5:00 PM	Development to Deployment of Cardiovascular AI	Pierre Elias, MD	
5:00 – 5:20 PM	Q & A		
5:20 – 5:30 PM	Annual ASPC Business Meeting		
<b>5:30 – 6:30 PM</b>	<b>Networking Break / Oral Abstract Presentations</b>		
<b>6:30 – 7:30 PM</b>	<b>Welcome Reception</b>		
<b>7:30 – 9:30 PM</b>	<b>Dinner Symposium</b>		

## Saturday, August 2, 2025

<b>Session</b>	<b>Name of Session</b>	<b>Speaker / Moderator</b>
<b>8:00 – 8:45 AM</b>	<b>Expert Theater Breakfast Presentations</b>	
8:55 – 9:00 AM	Day 2 Welcome	
<b>Session 6</b>		<b>Discussions and Debates in Preventive Cardiology</b>
<b>The Best Way to Assess Risk in YOUNG Adults</b>		
9:00 – 9:10 AM	Risk Factors	Sadiya Khan, MD, MSc
9:10 – 9:20 AM	Polygenic Risk Score	Pradeep Natarajan, MD, MMSC
9:20 – 9:30 AM	Imaging	Ron Blankstein, MD, FASPC

9:30 – 10:00 AM	Hormone Therapy Should Be Used for Prevention of ASCVD	Leslie Cho, MD (Pro) vs. Martha Gulati, MD, MS, MASPC (con)
10:00 – 10:30 AM	Serial Anatomic Imaging is the Best Way to Monitor Response to Therapy for Patients with Atherosclerosis	David Maron, MD, FASPC vs. Matthew Budoff, MD, FASPC
10:30 – 10:45 AM	Q & A	
<b>10:45 – 11:00 AM</b>	<b>Networking Break</b>	
<b>Session 7</b>	<b>Early Career Research Presentations</b>	<b>Larry Sperling, MD, MASPC</b>
11:15 AM – 12:05 PM	Early Career Research Presentations	<b>TBD</b>
<b>12:15 – 1:00 PM</b>	<b>Expert Theater Lunch Presentations</b>	
<b>Session 8</b>	<b>Career Phenotypes in Preventive Cardiology</b>	
1:15 – 1:30 PM	Clinical Research	Khurram Nasir, MD, MPH, FASPC
1:30 – 1:45 PM	Private Practice	Danielle Belardo, MD, FASPC
1:45 – 2:00 PM	Cardiovascular Imaging	Ron Blankstein, MD, FASPC
2:00 – 2:15 PM	Industry	Sergio Fazio, MD, PhD, FASPC
2:15 – 2:30 PM	Q & A	
<b>Session 9</b>	<b>Expanding the Scope: Prevention of Heart Failure and Atrial Fibrillation</b>	
2:30 – 2:35 PM	Patient with Atrial Fibrillation	Joe Dolan
2:35 – 2:50 PM	Prevention of Atrial Fibrillation	Christine Albert, MD, MPH
2:50 – 2:55 PM	Patient with Heart Failure	<b>TBD</b>
2:55 – 3:10 PM	Prevention of Heart Failure	Clyde Yancy, MD, MSc
3:10 – 3:30 PM	Q&A	
<b>3:30 – 4:00 PM</b>	<b>Networking Break</b>	
<b>Session 10</b>	<b>Case Presentations with Expert Faculty Panel</b>	
4:00 – 4:10 PM	Case 1: CAC score >1000, no Sx	Case 1: Arthur Shiyovich
4:10 – 4:25 PM	Discussion	
4:25 – 4:35 PM	Case 2: 3VD, No Sx	Case 2: Alexandra Smith
4:35 – 4:50 PM	Discussion	
4:50 – 5:00 PM	Case 3: Lipid management in pregnancy/breast feeding	Case 3: Amanda Jowell
5:00 – 5:15	Discussion	
5:15 – 5:20 PM	Early Career Research Winner Announcement	

<b>5:20 – 7:00 PM</b>	<b>Networking Break / Oral Abstract Presentations</b>
<b>6:30 – 7:30 PM</b>	<b>Abstract Author Reception</b>
<b>7:30 – 9:30 PM</b>	<b>Dinner Symposium</b>

## Sunday, August 3, 2025

Session	Name of Session	Speaker / Moderator
<b>8:30 – 9:30 AM</b>	<b>Breakfast Symposium</b>	
9:35 – 9:40 AM	Day 3 Welcome	
<b>Session 11</b>	<b>Sunday Keynote Address</b>	
9:40 – 10:00 AM	Universal Screening for LDL, CRP, and Lp(a)	Paul Ridker, MD, MPH
<b>Session 12</b>	<b>Exploring the Impact of GLP-1 Receptor Agonists</b>	
10:00 – 10:15 AM	Understanding GLP-1 Receptor Agonists: Mechanisms and Mechanisms of Action	Jorge Plutzky, MD
10:15 – 10:30 AM	The Heart of the Matter: GLP-1 Receptor Agonists and Cardiovascular Outcomes	Stephen Wiviott, MD
10:30 – 10:45 AM	The Next Frontier: Innovations and Future Research in GLP-1 Agonist Therapy	Christos Mantzoros, MD, DSc, PhD
10:45 – 11:00 AM	Who, When, and How: Guidelines for the Use of GLP-1 Receptor Agonists	Darren McGuire, MD, MHSc
11:00 – 11:15 AM	Q & A	
<b>11:15 – 11:30 AM</b>	<b>Networking Break</b>	
<b>Session 13</b>	<b>Hypertension</b>	
11:30 – 11:45 AM	Underrecognized, Undertreated, and Underappreciated	Karol Watson, MD, PhD, FASPC
11:45 AM – 12:00 PM	Lifestyle Interventions	Alison Bailey, MD, FASPC
12:00 – 12:15 PM	Novel Drug Therapy	Luke Laffin, MD
12:15 – 12:30 PM	Renal Denervation	Deepak Bhatt, MD, MPH
12:30 – 12:45 PM	Q & A	
12:45 – 1:00 PM	Closing Remarks & 2026 Announcement	